The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancy.
Adaptor Proteins, Signal Transducing
/ chemistry
Adenocarcinoma
/ metabolism
Animals
Carcinogenesis
/ metabolism
Cell Line, Tumor
Cell Transformation, Neoplastic
Gene Expression Regulation, Neoplastic
HEK293 Cells
Humans
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasm Invasiveness
Pancreatic Neoplasms
/ metabolism
Protein Isoforms
/ chemistry
RNA, Messenger
/ metabolism
Transcription Factors
/ chemistry
WW Domains
YAP-Signaling Proteins
Pancreatic Neoplasms
LATS1
WW domain
YAP1
isoform
pancreatic cancer
protein stability
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
12
2019
accepted:
02
03
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
2
4
2021
Statut:
epublish
Résumé
YAP1 is a key mediator of the Hippo pathway capable of exerting a profound effect on organ size as well as tumorigenesis. Alternative mRNA splicing of human YAP1 results in at least 8 protein isoforms that differ within the 2
Identifiants
pubmed: 32292505
doi: 10.7150/thno.42795
pii: thnov10p4422
pmc: PMC7150473
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Protein Isoforms
0
RNA, Messenger
0
Transcription Factors
0
YAP-Signaling Proteins
0
YAP1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4422-4436Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL126732
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL132156
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL146461
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Cell. 2017 May 18;169(5):807-823.e19
pubmed: 28479188
Oncogene. 2012 Jan 5;31(1):128-34
pubmed: 21685940
Oncogene. 2013 Aug 15;32(33):3922
pubmed: 23160371
Sci Signal. 2014 May 06;7(324):ra42
pubmed: 24803537
Gene. 2012 Nov 10;509(2):215-22
pubmed: 22939869
Sci Rep. 2015 Nov 16;5:16759
pubmed: 26567630
Cell Death Dis. 2014 Mar 27;5:e1142
pubmed: 24675460
Oncol Rep. 2018 Jul;40(1):16-28
pubmed: 29749524
Nat Rev Cancer. 2013 Apr;13(4):246-57
pubmed: 23467301
Cancer Lett. 2014 Dec 28;355(2):201-9
pubmed: 25218593
Nucleic Acids Res. 2012 Jan;40(Database issue):D302-5
pubmed: 22053084
Int J Mol Sci. 2016 Jan 21;17(1):
pubmed: 26805820
Dev Cell. 2010 Oct 19;19(4):491-505
pubmed: 20951342
J Biol Chem. 2008 Oct 10;283(41):27534-46
pubmed: 18640976
PLoS One. 2015 Jan 21;10(1):e0113828
pubmed: 25607641
Cancer Biol Ther. 2013 May;14(5):390-8
pubmed: 23380592
J Biol Chem. 1995 Jun 16;270(24):14733-41
pubmed: 7782338
J Hematol Oncol. 2017 Apr 19;10(1):91
pubmed: 28420424
J Biol Chem. 2013 May 24;288(21):15181-93
pubmed: 23564455
Br J Cancer. 2011 Jan 4;104(1):24-32
pubmed: 21102585
Nat Commun. 2016 Feb 15;7:10498
pubmed: 26876920
J Neurosci. 2014 Sep 3;34(36):12039-48
pubmed: 25186749
Cell. 2014 Jul 3;158(1):185-197
pubmed: 24954535
Oncogene. 2013 Mar 7;32(10):1266-73
pubmed: 22525271
Theranostics. 2018 Feb 2;8(5):1256-1269
pubmed: 29507618
Genes Dev. 2012 Sep 1;26(17):1959-71
pubmed: 22948661
Cell. 2014 Jul 3;158(1):171-84
pubmed: 24954536
Theranostics. 2017 Feb 27;7(5):1114-1132
pubmed: 28435452
Front Biosci (Landmark Ed). 2012 Jan 01;17:331-48
pubmed: 22201747
J Biol Chem. 2008 Oct 10;283(41):27462-8
pubmed: 18701449
Theranostics. 2018 May 11;8(12):3256-3267
pubmed: 29930727
Genes Dev. 2008 Jul 15;22(14):1962-71
pubmed: 18579750
Biochem Biophys Rep. 2016 Mar 03;6:24-31
pubmed: 28018981
Trends Biochem Sci. 2010 Nov;35(11):627-33
pubmed: 20598891
Gastroenterology. 2016 Sep;151(3):526-39
pubmed: 27215660
Nat Commun. 2013;4:2251
pubmed: 23903990
Nature. 2018 Feb 1;554(7690):62-68
pubmed: 29364867
Theranostics. 2017 Sep 15;7(16):3972-3988
pubmed: 29109792